Precisely engineered honeycomb-like C-ZIF67 aptasensor array for integrated detection of multiple cardiac biomarkers
Jie He1, Mengxin Deng1, Shijian Huang2
1Guangdong Provincial Key Laboratory of Optical Information Materials and Technology, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, 510006, PR China.
None:
Early and precise diagnosis of acute myocardial infarction (AMI) is crucial for reducing mortality and improving therapeutic outcomes in cardiovascular diseases (CVDs). Integrated detection of multiple biomarkers, creatine kinase-myocardial band (CK-MB), cardiac troponin I (cTnI), and myoglobin (Mb), provides a reliable strategy for timely AMI diagnosis and prognosis evaluation. Herein, an integrated electrochemical aptasensor array modified with multilayered honeycomb-like porous structure carbonized ZIF67 (h-porous C-ZIF67) was designed and constructed for multiplex detection of CK-MB, cTnI and Mb in plasma samples. The laser-etched electrode array provided uniform and well-defined sensing units, while the h-porous C-ZIF67 modifier was constructed in situ using opal template transfer, precursor infiltration, spin coating, and high-temperature carbonization. Aptamers specific toward each biomarker were immobilized on the modified surface, and horseradish peroxidase (HRP)-catalyzed signal amplification enhanced detection sensitivity. The aptasensor array demonstrated wide linear ranges (1.0 pg/mL-100.0 ng/mL) and low detection limits of 0.38 pg/mL, 0.03 pg/mL, and 0.42 pg/mL for CK-MB, cTnI, and Mb, respectively. The layer-by-layer assembly provided precise control over modifier thickness and architecture, addressing reproducibility issues associated with conventional surface modification. By integrating tunable porous modifiers, multiplexed electrode units, aptamer recognition, and catalytic amplification, the platform achieved rapid, sensitive, and quantitative multiplex analysis of the AMI biomarkers. Compared with conventional immunoassays, the array demonstrated shorter detection time, improved reproducibility, and robust multiplexing capability. These findings highlight the potential of the proposed aptasensor array as a point-of-care testing (POCT) platform for early AMI diagnosis and broader clinical applications.
